<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230200</url>
  </required_header>
  <id_info>
    <org_study_id>SCREEN-Pan Cancer</org_study_id>
    <nct_id>NCT04230200</nct_id>
  </id_info>
  <brief_title>Prospective Screening Programme for Malignant Tumors</brief_title>
  <official_title>A Large-scale, Prospective Screening Programme for Malignant Tumors Using Routine Blood Tests Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In prospective part of study, the investigators have found that the parameters of routine
      blood tests can differentiate varieties of malignancy from healthy people.

      The investigators enrolled healthy subjects and patients with malignancy that aged from 18 to
      85，and collected their clinical data and blood tests result to build the model.And
      retrospectlly enroll healthy subjects and patients to test the model.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity (true positive rate)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of persons with disease who have a positive test (positive test results among persons with disease)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity (true negative rate)</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of persons without disease who have a negative test (negative test results among persons without disease)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hematologic Tests</condition>
  <condition>Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>Healthy cohort</arm_group_label>
    <description>People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignancy Cohort</arm_group_label>
    <description>People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Malignant tumor is a common Threat to human health worldwide. Some of the routine blood
        tests parameters were reportedly predictive of the risk of Malignant tumor. This study aims
        to investigate whether routine blood tests parameters would be useful in the screening of
        Malignant tumor in asymptomatic individuals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For the cohort of healthy people

        Inclusion Criteria:

          1. Asymptomatic persons between the ages of 18 to 80 years

          2. Chinese ethnicity

          3. After 3 year follow-up, diagnosed with no malignant disease

          4. Subject underwent routine blood tests in our center

        Exclusion Criteria:

        1.With a history of malignant disease

        For the cohort of patients with malignancy

        Inclusion Criteria:

          1. diagnosis with the following malignant disease，breast cancer, lung cancer, gastric
             cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and
             cervical cancer

          2. Subject underwent routine blood tests in our center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.</citation>
    <PMID>28130846</PMID>
  </reference>
  <reference>
    <citation>Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, Chan G, Hui EP, Ma BBY, Chiu RWK, Leung SF, van Hasselt AC, Chan ATC, Lo YMD. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017 Aug 10;377(6):513-522. doi: 10.1056/NEJMoa1701717. Erratum in: N Engl J Med. 2018 Mar 8;378(10 ):973.</citation>
    <PMID>28792880</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

